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Abstract
Genome-wide association studies (GWAS) in immune-mediated diseases have identified over 150 associated genomic loci.
Many of these loci play a role in T cell responses, and regulation of T cell differentiation plays a critical role in immune-
mediated diseases; however, the relationship between implicated disease loci and T cell differentiation is incompletely
understood. To further address this relationship, we examined differential gene expression in naı ¨ve human CD4+ T cells, as
well as in in vitro differentiated Th1, memory Th17-negative and Th17-enriched CD4+ T cells subsets using microarray and
RNASeq. We observed a marked enrichment for increased expression in memory CD4+ compared to naı ¨ve CD4+ T cells of
genes contained among immune–mediated disease loci. Within memory T cells, expression of disease-associated genes was
typically increased in Th17-enriched compared to Th17-negative cells. Utilizing RNASeq and promoter methylation studies,
we identified a differential regulation pattern for genes solely expressed in Th17 cells (IL17A and CCL20) compared to genes
expressed in both Th17 and Th1 cells (IL23R and IL12RB2), where high levels of promoter methylation are correlated to near
zero RNASeq levels for IL17A and CCL20. These findings have implications for human Th17 celI plasticity and for the
regulation of Th17-Th1 expression signatures. Importantly, utilizing RNASeq we found an abundant isoform of IL23R
terminating before the transmembrane domain that was enriched in Th17 cells. In addition to molecular resolution, we find
that RNASeq provides significantly improved power to define differential gene expression and identify alternative gene
variants relative to microarray analysis. The comprehensive integration of differential gene expression between cell subsets
with disease-association signals, and functional pathways provides insight into disease pathogenesis.
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Introduction
Genome-wide association studies in immune-mediated diseases
have implicated a variety of inflammatory pathways, with a striking
overlap of major association signals across disease subtypes [1].
One of the most significant is the interleukin 23 (IL-23) pathway,
highlighted by associations within the IL23R (interleukin 23
receptor, alpha chain) gene region to inflammatory bowel disease
(IBD) [2], psoriasis [3], and ankylosing spondylitis [4]. Interleukin
23 (IL-23) is required for the optimal expansion and maintenance
of Th17 lymphocytes, a key pro-inflammatory cell subset [5].
Within IBD, a striking number of the top association signals
include genes along the IL-23 signaling pathway, including
STAT3, IL12B (p40, a component of the heterodimeric IL-23
cytokine; also part of IL-12), JAK2 and TYK2 [6,7,8], although
these genes are not specific to IL-23 signaling. In addition, genes
enriched in Th17 cells, such as CCR6, have also been associated
with IBD [8].
Human Th17 cells are characterized by the selective expression
of CD161, CCR6 (chemokine C-C motif receptor 6), IL23R and
the master transcription factor, RORC [9]. Th17 cells arise from
a CD161+CD4+ T cell precursor [10,11,12] and CCR6 plays
a key role in Th17 cell trafficking to the intestine [13,14].
Importantly, Th17 cells also expressing IFNc are abundant in the
gut of patients with Crohn’s disease, a subtype of IBD [15]. The
traditional view of an initiating role of IFNc, IL-12 and Th1 cells
in immune-mediated human and disease models of autoimmunity
has been revised both by human genetic association studies
implicating the IL-23 pathway, as well as the requirement for IL-
23, and not the IL-12 pathway, in mouse models of intestinal,
dermatologic and central nervous system inflammation
[16,17,18,19].
Given the preponderance of IL-23 pathway and Th17
enriched genes associated with immune-mediated diseases, we
sought to more precisely define the spectrum and molecular basis
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Th1, Th17-negative and Th17-enriched CD4+ memory T cell
subsets. We observed an enrichment of immune-mediated disease
genes among upregulated genes in CD4+ memory compared to
naı ¨ve T cells and also among upregulated genes in Th17-
enriched CD4+ T cells compared to Th17-negative expanded
memory CD4+ T cells. We demonstrate evidence for an
abundant, novel isoform in IL23R predicted to terminate prior
to the transmembrane domain. The differential mechanisms of
gene regulation observed between initial Th17-lineage defining
genes such as IL17A, IL17F and CCL20, compared to genes
induced in both Th17 and Th1 cells, such as IL23R and
IL12RB2, provide insight into the sequential and versatile roles
that Th17 cells play in immune health and disease.
Results
The Surface Markers CD161 and CCR6 Distinguish Th17-
negative from Th17-enriched CD4+ Memory Cell Subsets
To explicitly compare Th17-enriched with Th17-negative cells,
we sorted freshly isolated human CD4+ memory T cells into
CD161+CCR6+ and CD161-CCR6- subsets (Figure 1A), and
expanded these cells for seven days with anti-CD3 and anti-CD28
mAb in the presence of IL-23 and IL-1b. Intracellular staining of
IL-17 and IFN demonstrates that expanded CD161-CCR6- cells
express minimal IL-17 (Figure 1B); in contrast, a significant
fraction of expanded CD161+CCR6+ cells produces IL-17 (25–
52%, Th17-enriched). Comparable fractions of expanded CD161-
CCR6- and CD161+CCR6+ cells express IFNc; as expected,
these fractions are lower than those attained by expansion of naı ¨ve
CD4+ T cells under Th1-skewing conditions (range, 72–80%)
(Figure 1B). Within the expanded memory CD161+CCR6+
subset, 10–15% of cells express IL-17 but not IFNc, whereas
15–40% of cells express both IL-17 and IFNc, reflecting
heterogeneity of gene expression within Th17-cell subsets
(Figure 1B).
Improved Power to Identify Differential Gene Expression
with RNASeq Compared to Expression Microarrays
To accurately evaluate differential gene expression in naı ¨ve, in
vitro differentiated Th1, Th17-negative and Th17-enriched CD4+
T cell subsets from healthy individuals, we utilized both
microarray and transcriptome sequencing (RNASeq) [20] and
compared the results. Gene expression was measured by the
estimated number of fragments of RNA per kilobase of exon per
million fragments mapped (FPKM) for RNASeq and by log2
normalized intensity for microarray analysis (Figure S1). The gene
expression estimates generated by the two approaches were
strongly correlated (r =0.83 - 0.85) for all four cell subsets (Figure
S1). Of note, the correlation between the two expression estimates
was much smaller when restricting to transcripts with lower
FPKMs because of the high level of background noise inherent in
the microarray platform (r =0.38 - 0.45 for transcripts with
RNASeq FPKM less than the median).
We next tested for differential gene expression between Th1 vs.
naı ¨ve and Th17-enriched vs. Th17-negative cells, comparing
RNASeq with expression microarrays. The distribution of the P-
values obtained from the RNASeq and microarray experiments
using Q-Q plots (Figure 2A and 2C) and bar plots (Figure 2B and
2D) demonstrated a marked increase in the number of highly
significant differentially expressed genes when expression was
measured by RNASeq. Since a comparable number of samples
were used for the two approaches (n=5 for expression micro-
arrays, n=4 for RNASeq), this indicates that there is markedly
greater power to identify differential gene expression using
RNASeq compared to expression microarrays. The improved
power of RNASeq reflects the numerous sequence reads obtained
from analysis of a single sample, compared to the single intensity
measurement obtained from microarray expression measure-
ments, thereby allowing the more precise measurement of low
transcript abundance compared to microarray-based measure-
ments of gene expression.
Significant Enrichment for Increased Expression of Genes
within Immune-mediated Genetic Loci in CD4+ Memory
Compared to Naı ¨ve CD4+ T Cells and in Th17-enriched
Compared to Th17-negative Expanded Memory CD4+ T
Cells
The Immunochip was designed to densely map loci demon-
strating genome-wide significant evidence for association to one of
nine immune-mediated diseases using 0.1 cM (centimorgan)
flanking boundaries from the peak association signal [21]. Loci
related to 12 immune-mediated diseases were included on this
custom chip. We extracted 1387 genes related to the loci from the
Ensembl gene reference set, which we refer to as immune-
mediated disease transcript subset. We hypothesized that such
genes would demonstrate differential gene expression in CD4+ T
cell subsets, since they surround or flank immune-mediated disease
loci. Using RNASeq and microarray-based expression in CD4+ T
cell subsets, we evaluated differential gene expression for all
combinations of CD4+ T cells. We then tested for enrichment of
the 1387 Immune-Mediated Disease Transcripts among upregu-
lated genes (defined as those genes having P-values for upregula-
tion amongst the 5% most significant P-values) using Fisher’s exact
test for each comparison.
Table 1 reports the enrichment P-values obtained for relative
gene expression for each possible pair of cell subsets using both the
RNASeq and microarray datasets. First, we observed significant
enrichment of immune-mediated disease transcripts among
transcripts up-regulated in CD4+ memory T cells compared
CD4+ naı ¨ve T cells. Specifically, in the RNASeq analysis,
significant enrichment of disease-associated transcripts were
observed comparing Th17-enriched memory to naı ¨ve CD4+ T
cells (P-value =7.63610
204), with similar, more modest enrich-
ment of Th17-negative memory compared to naı ¨ve CD4+ T cells
(P-value =0.019). Similar, less significant trends are observed in
the microarray data; enrichment P-values comparing Th17-
enriched memory cells to naı ¨ve CD4+ T cells and Th17-negative
cells vs. naı ¨ve CD4+ T cells 0.025 and 0.091, respectively.
Secondly, within memory CD4+ T cells, significant enrichment of
immune-mediated disease transcripts was detected in genes
upregulated in Th17-enriched compared to Th17-negative
CD4+ memory T cells with the RNASeq analysis (P-value
=2.46610
203). This enrichment was consistently, but less
significantly detected in the microarray dataset (P-value
=0.043). Finally, comparing CD4+ memory T cells and in vitro
differentiated Th1 cells, we observed a significant enrichment for
upregulated in Th17-negative compared to Th1 (P=1.13610
203)
and Th17-enriched compared to Th1 (P=7.24610
203) with
RNASeq analyses; the P values of the same comparisons in
microarray data were rather modest, 0.09 and 0.11 respectively,
likely reflecting the lower power of microarray data to identify
differential gene expression. Taken together, these data highlight
the central role of genes demonstrating enriched expression in
CD4+ memory cells generally, and memory Th17 CD4+ T cells
specifically, in immune-mediated disease pathogenesis.
Effector CD4+ T Cell Expression Signatures
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(genes upregulated in Th17-enriched memory comparing to
Th17-negative memory CD4+ T cells) among autoimmune-
disease associated genes, we have identified the known disease
associations for each pertinent transcript using the GWAS catalog
[22], (Table S1 for RNASeq; Table S2 for microarray data).
Genes were selected for this annotation based on satisfying all of
the following three criteria: 1) having a P-value less than 0.05 for
differential expression between Th17-enriched and Th17-negative
memory CD4+ T cells, (2) being upregulated in Th17-enriched
cells and (3) appearing in both the microarray and RNASeq
datasets. The genes are ordered by P-value for upregulation in
Th17-enriched compared to Th-17 memory CD4+ T cells.
To further explore the Th17 cell expression signature, we
performed cluster analysis focusing on the transcripts demonstrat-
ing increased expression in Th17-enriched cells relative to Th17-
negative cells by using Partek Genomics Suites (Partek, MO). 195
transcripts with P-values less than 10
209 were used for the cluster
analysis of the RNASeq dataset (Figure 3), and 147 transcripts
with at least a 1.5 fold change and P-values less than 0.05 were
used for the clustering analysis of the Microarray dataset (Figure
S2). We compared the patterns of expression in Th17-enriched,
Th17-negative, CD4+ naı ¨ve and in vitro differentiated Th1 cells.
As expected, the samples from each of the four cell types clustered
together. Because the selection criteria for transcript inclusion was
based on increased expression in Th17-enriched compared to
Th17-negative cells, increased expression (red-colored predomi-
nance) is observed in Th17-enriched compared to Th17-negative
cells (blue-colored predominance). Asterisks (*) designate the
transcripts within immune-mediated disease regions; there were
a total of 32 such transcripts in the whole cluster (Figure 3,
indicating that these immune-mediated disease transcripts are
highly expressed in Th17-enriched CD4+ T cells. In addition,
these immune-mediated disease transcripts are not exclusively
expressed in Th17-enriched memory T cells. Nearly half are
highly expressed in both Th17-enriched memory and in vitro
differentiated Th1 cells, for instance, IL23R, IL12RB2, IL18RAP,
and CTSH. Similarly, in the microarray cluster (Figure S2), there
were a total of 25 immune-mediated disease transcripts in the total
147 transcripts. These clustering analyses demonstrate the
Figure 1. CD4+ T cell subsets. A. CD4+CD25- T cells were sorted by flow cytometry into CD45RO- and CD45RO+ subsets. Memory CD4+CD25-
CD45RO+ cells were sorted into CD161+ CCR6+ and CD161-CCR6- subsets for subsequent activation and expansion. B. Th1 cells were generated from
naı ¨ve CD4+CD62L+CD25-CD45RO- T cells by activating and expanding with anti-CD3, anti-CD28 in the presence of IL-12 and anti-IL4 for seven days.
CD161+CCR6+ and CD161-CCR6- memory CD4+ T cells were activated and expanded with anti-CD3, anti-CD28, IL-1b and IL-23 for seven days. The
distinct T cell subsets were assessed for differentiation by intracellular cytokine staining for IL-17A and IFNc expression. Representative flow
cytometry plots are shown in the figure.
doi:10.1371/journal.pone.0038510.g001
Effector CD4+ T Cell Expression Signatures
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can also be seen in Figure S1). Taken together, these data support
the conclusion from the enrichment analysis that immune-
mediated disease transcripts are enriched among transcripts
upregulated in Th17-enriched CD4+ memory T cells.
Promoter Methylation Patterns Contribute to Differential
Gene Expression in CD4+ T Cell Subsets
Gene expression is regulated at multiple levels, including
promoter methylation, covalent modification of histones, interac-
tions with non-coding RNAs, and post-translational modifications.
We investigated the promoter DNA methylation patterns of
illustrative genes in CD4+ T cell subsets, selecting two transcripts
demonstrating increased expression in both Th17-enriched and
Th1 cells (IL23R and IL12RB2), as well as two transcripts
demonstrating increased expression solely in Th17-enriched cells
(IL17A, CCL2)), compared with two transcripts demonstrating
increased expression (Figure 4, Figure S3). High levels of
methylation at conserved CpG sites result in gene silencing [23];
however, additional levels of gene regulation contribute, as gene
expression is imperfectly correlated with promoter methylation
levels alone [24]. For example, IL23R and IL12RB2 are adjacent
on chromosome 1p31; despite similar patterns of gene expression
of these two genes across CD4+ T cell subsets (Figure 3), very
different patterns of promoter methylation are observed compar-
ing IL23R and IL12RB2 (Figure 4A–B). In the IL23R promoter,
high levels of CpG methylation and gene silencing are observed in
naı ¨ve CD4+ T cells (Figure 4A), with significantly lower levels
observed in CD4+ memory subsets, including Th17-negative cells
that express low levels of IL23R. In contrast, IL12RB2 promoter
Figure 2. Improved power to identify differential gene expression with RNAseq. A. Q-Q plot for observed and expected P-Values for
differential gene expression comparing in vitro differentiated Th1 and Naı ¨ve CD4+ T cells (N=4). B. Observed statistical significance for differential
gene expression between in vitro differentiated Th1 and Naı ¨ve CD4+ T cells (N=4). C. Q-Q plot for observed and expected P-values for differential
gene expression comparing Th17-enriched and Th17-negative CD4+ memory T cells. D. Observed statistical significance for differential gene
expression between Th17-enriched and Th17-negative CD4+ T cells.
doi:10.1371/journal.pone.0038510.g002
Effector CD4+ T Cell Expression Signatures
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38510methylation levels are low in all CD4+ subsets (Figure 4B), even in
naı ¨ve CD4+ T cells, reflecting a fundamental difference in
regulation of gene expression between IL23R and IL12RB2.
Using RNASeq, differential gene expression between cell
subsets associated with the complete absence of mRNA expression
can be defined, such as the absence of IL17A sequences in Th17-
negative subsets; the distinction between the complete absence of
gene expression and present, but relatively decreased, gene
expression levels, suggests distinct mechanisms of gene regulation.
For example, while marked induction of gene expression in Th17-
enriched compared to Th17-negative cells is observed for IL23R,
IL12RB2, IL17A and CCL20, the latter two Th17 signature genes
have RNASeq counts in Th17-negative cells near zero (Figure 4E).
Consistent with this, high methylation levels (fraction methylated
greater than 0.7) are observed at conserved CpG sites within the
IL17A (Figure 4C), IL17F (Figure S3B) and CCL20 (Figure 4D)
promoters in all CD4+ T cell subsets examined except for Th17-
enriched cell subsets. Therefore, with IL17A, IL17F and CCL20,
promoter methylation levels account for much of the variable gene
expression observed between CD4+ T cell subsets. However, with
IL23R and IL12RB2, promoter methylation levels are less well
correlated; for example, modest trends toward decreased CpG
methylation (and therefore increased gene expression) in Th17-
enriched compared to Th17-negative cells is observed. While CpG
promoter methylation levels are comparable between Th1 and
Th17-negative cells, IL23R gene expression levels are much higher
in Th1 cells (Figure 4E).
Identification of a Major, Novel IL23R Truncated Isoform
Inspection of the mapped sequence reads in the IL23R gene
region on chromosome 1p31 in Th17-negative and positive cells
revealed a striking increase of expressed sequences in the intronic
region immediately centromeric to exon 6, particularly in Th17-
enriched cells and in vitro differentiated Th1 cells (Figure 5A). The
y-axis scale represents RNASeq coverage, and indicates that
IL23R was highly expressed on both Th17-enriched and in vitro
differentiated Th1 cells. Also, IL23R expression is higher in in vitro
differentiated Th1 cells compared to Th17-enriched CD4+
memory T cells. Examination of paired sequence reads
(Figure 5B) confirmed numerous examples where the sense
sequence originated in the coding portion of exon 6, and its
Table 1. Immune-mediated-associated gene enrichment
analysis.
Test RNASeq Microarray
Th17-negative.Th17-enriched 0.099 0.52
Th17-enriched.Th17-negative 2.46E203 0.043
Th1.Naı ¨ve 0.033 0.67
Naı ¨ve.Th1 0.025 0.62
Th17-enriched.Th1 7.24E203 0.11
Th1.Th17-enriched 0.63 0.95
Th17-enriched.Naı ¨ve 7.63E204 0.025
Naı ¨ve.Th17-enriched 0.63 0.28
Th17-negative.Naı ¨ve 0.019 0.091
Naı ¨ve.Th17-negative 0.14 0.95
Th17-negative.Th1 1.13E203 0.09
Th1.Th17-negative 0.24 0.98
Enrichment analysis performed by Fisher’s 262 test for the 5% of the most
differentially expressed genes between the two compared cell subsets. Bolded
are P-values less than 0.004.
doi:10.1371/journal.pone.0038510.t001
Figure 3. Preponderance of disease-associated transcripts
upregulated in Th17 and in vitro differentiated Th1 cells.
Hierarchical clustering was performed on 195 transcripts with increased
expression in Th17-enriched (red, increased expression relative to other
cell types) compared to Th17-negative (blue, decreased expression) and
differential expression P-values less than 1610
209.A s t e r i s k s( * )
designate the transcripts within immune-mediated disease loci. There
are total 32 immune-mediated disease associated genes with names
marked in the figure.
doi:10.1371/journal.pone.0038510.g003
Effector CD4+ T Cell Expression Signatures
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consensus sequence. Continuation of transcripts into the consensus
intron 6 region would result in a stop signal 9 codons downstream
of the consensus exon 6 sequence. The transmembrane domain of
IL23R is contained within exon 9, with the extracellular domain
encoded by exons 2 through 8. We performed 39 RACE priming
from the coding region of exon 6 followed by sequence analysis,
and confirmed the presence of a major transcript continuing into
the region adjacent to the consensus exon 6 region resulting in an
extended form of exon 6 (,700 base pair amplicon, Figure 5C), as
Figure 4. Differential gene expression between CD4+ T cell subsets results from distinct molecular mechanisms. Shown are the
fractions of methylation at conserved CpG promoter sites estimated by mass spectrometry (N=5) for A. IL23R,B .IL12RB2,C .IL17A and D. CCL20
promoters. Paired t-tests were used to test for differential methylation fractions between naı ¨ve vs. Th1 and Th17-negative vs. Th17-enriched were
estimated by paired t-test; *P,0.05, **P,0.01, ***P,0.001. E. Average expression estimates from four individulas in both RNASeq and microarray
show that Th17-specific transcripts IL17A and CCL20 have nearly zero expression in Th17-negative cells, corresponding to high promoter methylation
levels (C–D). Gene expression was measured by FPKM (fragments of RNA per Kilobase of exon per Million fragments mapped) for RNASeq and log2
RMA normalized intensity for microarray.
doi:10.1371/journal.pone.0038510.g004
Effector CD4+ T Cell Expression Signatures
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pair fragment, Figure 5C). The presence of PCR amplicons
priming between the non-coding region of the extended exon 6 to
sense primers in each of exons 2–5 was also confirmed (Figure S4).
In the 39 RACE analysis priming from the coding region of exon
6, the early truncating transcript extends 672 base pairs into the
consensus intron 6 region (67,672,739 to 67,673,410 base pairs).
In four donors, using Cufflinks applied to a custom annotation file
for the IL23R region, we observed a high fraction of this IL23R
transcript with an extended form of exon 6, (32.78% 64.70% for
Th17-enriched and 42.80% 60.28% for in vitro differentiated
Th1 cells). The sequences mapping immediately centromeric to
this are largely self-contained, with sequence pairs mapping
between 67,673,962 to 67,675,317 base pairs, forming an
independent transcript (Figure 5B, zoom-in picture of intron 6).
This independent RNA is expressed in both Th17-enriched and in
vitro differentiated Th1 cells (Figure 5A), highlighting both the
abundance and regulated nature of such novel transcripts.
Discussion
Enrichment of CD4+ T Cell Gene Signatures in Immune-
mediated Disease Loci
The overlap of associated genetic loci identified by GWAS
across immune-mediated diseases suggests a shared pathogenesis.
Commonly, the precise risk alleles are also the same, suggesting
that the overlap results not merely from the identification of key
immune-mediated genes with functional polymorphisms, but that
the directionality of effects is also shared. In this study, we observe
that genes contained within immune-mediated disease genetic loci
demonstrate a striking enrichment of increased gene expression in
Th17-enriched, Th17-negative CD4+ memory compared to naı ¨ve
CD4+ cells (Table 1). Within memory CD4+ T cells, we observe
increased gene expression in Th17-enriched compared to Th17-
negative cells. Importantly, enrichment of increased gene expres-
sion in the converse direction is not observed; for example, genes
demonstrating increased gene expression in naı ¨ve CD4+ T cells
compared to memory T cells are not enriched among disease-
associated genes. These findings provide a basis for an increasingly
refined and systematic, directional molecular mapping between
disease associations and altered function of CD4+ T cell subsets.
It might be anticipated that a Th17 or Th1 enrichment
signature would be obscured by the broad inclusion of all
transcripts within association signals, as clearly not all genes in
associated regions contribute to disease pathogenesis. The
presence of a clear Th17 and Th1 expression signature highlights
the precise and significant enrichment provided by the composite
information gleaned from GWAS across immune-mediated
diseases. Furthermore, the commonly observed concordance of
expression for genes closely linked in the genome also contributes
to the enrichment signature observed. The close clustering of
IL23R and IL12RB2 (chr1p31) is consistent with this. This
concordance of expression for closely linked genes also suggests,
in some cases, a limitation in defining a single gene driving what
are often complex, extended and multiple disease associations
within a particular locus.
Association, Expression and Functional Overlap between
IL-23 and IL-12 Pathways
Within the IL23R-IL12RB2 locus, several independent SNPs
have been associated with multiple immune-mediated diseases. A
protective missense mutation in IL23R, Arg381Gln, has been
reported to be a loss-of-function allele [25,26], indicating that
increased IL-23 signaling increases immune-mediated disease risk.
Multiple independent association signals are observed within the
IL23R gene region and the intergenic region between IL23R and
IL12RB2. While cis-acting eQTLs are present within IL12RB2
[27], these eSNPs are not correlated with disease association
signals. No eQTLs and allelic imbalance have been reported for
IL23R. The absence of correlations between mRNA levels and
single SNPs associated with disease could reflect more complex
mappings between disease-associated polymorphisms and gene
expression. One possibility is that haplotypes in the IL23R-
IL12RB2 gene region confer greater disease risk; consistent with
this, GWAS-derived haplotypes provide superior predictive
capacity for disease risk in Crohn’s disease compared to single-
marker models [28] suggesting improved biologic modeling with
haplotypes. Additional possibilities are that disease-associated
polymorphisms may modulate gene expression only in specific
biologic contexts (e.g. cellular activation), that the key alteration in
gene expression may be post-transcriptional, or that disease-
associated polymorphisms may modulate relative expression of
alternative isoforms.
The abundance of an IL23R isoform terminating at exon 6,
which would not encode the transmembrane domain, suggests that
IL23R isoforms play a significant role in gene regulation. The
abundance of sequence reads in consensus intron 6 indicates that
transcripts terminating in an extended exon 6 are highly prevalent.
A recent study reported an isoform lacking the exon 9, trans-
membrane domain (D9) [29]. This alternative isoform would
encode for a soluble form of IL23R, and comprised approximately
10% of IL23R isoforms. However, this study performed mass
spectrometry on amplified cDNA using primers from exons 2 and
11, and could therefore not identify the major isoform terminating
in an extended exon 6. Whether the non-coding disease-associated
polymorphisms in the IL23R gene region modulate the relative
fraction of exon 6 terminating compared to full-length IL23R will
be the subject of future studies; ongoing, large scale, fine-mapping
association studies performed using Immunochip may provide
important insight.
IL-12 and IL-23 play central, proliferative roles in Th1 (IFNc-
expressing) and Th17 (IL-17 expressing) cells, respectively.
Expression patterns of IL23R and IL12RB2 are similar across
CD4+ T cell subsets, with both induced in Th17-enriched and
Th1 subsets, relative to Th17-negative and CD4+ naı ¨ve cells,
respectively. In fact, expression of IL23R is relatively higher in
vitro differentiated Th1 compared to Th17-enriched subsets. In
CD4+CD45Rb
HI IL23R2/2 T cell transfer models, IL23R2/2
T cells demonstrated normal Th1 differentiation. However, in the
intestine CD4+CD45Rb
HI IL23R2/2 T cells showed impaired
proliferation, decreased accumulation, and reduced expression of
IL-17+IFNc+ cells [19]. Therefore, multiple factors regulate the
downstream consequences to T cell subset outcomes in addition to
the regulated expression of select proteins.
Importantly, Th17 cells demonstrate substantial plasticity after
their initial commitment to the Th17 program [30,31]; IL-12 can
extinguish RORct and IL17 expression in Th17 cells [15] through
covalent histone modifications resulting in epigenetic silencing of
the IL17A-IL17F and RORC genes and enhancement of IFNc
expression. In fact, using cell fate mapping in the experimental
autoimmune encephalomyelitis (EAE) model, proinflammatory
cytokines in the spinal cord were produced almost exclusively by
‘‘ex-Th17 cells’’ [32]. The specialized, sequential functions of the
Th17 and Th1 pathways [33] in jointly mediating mucosal
inflammation have yet to be fully defined. It is possible that the
Th17 pathway plays an essential initiating and amplifying role in
mucosal inflammation through its joint expression of the
chemokine receptor, CCR6 [34], and its ligand, CCL20, which
Effector CD4+ T Cell Expression Signatures
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38510Figure 5. Abundantly expressed, novel IL23R isoform. A. Sequence reads were mapped to the IL23R gene region in Th17-enriched and in vitro
differentiated Th1 cells using Tophat v1.3.3. The intron 6 region was highly covered in both the Th17-enriched and Th1 cell subsets. The scale on the
y-axis represents coverage (average number of reads that cover a particular base). B. Zoom in picture of extended coverage on exon 6 and intron 6.
Blue and red bars correspond to sense- and anti-sense reads, respectively. The expanded inset demonstrates sequence reads mapping to an
extended exon 6 resulting in a stop signal 9 codons downstream with contiguous 39UTR sequence; in addition an independent transcript maps
immediately centromeric to this. C. 39 RACE (rapid amplification of cDNA ends) was performed, and 2000 and 700 base pair fragments were
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Consistent with this, demethylation of IL17A and CCL20
promoter CpG sites plays a key role in initial Th17 program
commitment (Figure 4C–D). The presence of repressive
H3K27me3 epigenetic marks throughout the CCR6 gene region
in murine-derived Th1 cells [35] further supports the concept that
a key feature of Th17 cells involves its efficient transport to
mucosal sites. Teleologically, it has been proposed that the
versatility of Th17 cells to adjust its effector program as needed
allow them to respond most efficiently to early and late immune
clearance requirements, as well as to a broad range of mucosal
pathogens which ultimately might confer significant evolutionary
benefit [30].
Toward a Comprehensive Molecular Integration of
Disease Association Signals and Differential Gene
Expression
The enrichment of Th17-Th1 expression signatures for genes
contained within immune-mediated genetic loci implies, but does
not establish, a directionality of disease-associated polymorphisms
on gene expression and function. A key next step in this regard is
the performance of fine-mapping studies using large case-control
cohorts to refine independent and dependent SNPs and haplotypes
that account for observed association signals. RNASeq data
provides a useful adjunct to eQTL mapping [36] by providing
molecular mapping to variable gene expression. Alternative
isoforms, post-transcriptional regulation and regulation in select
biologic conditions likely also contribute to disease-associated
regulation of gene expression. Integration of allele and haplotype-
based variable gene expression with disease association results
from large fine-mapping studies will provide an important
foundation toward developing increasingly refined models of gene
expression and disease networks.
Materials and Methods
Cell Preparation
This study has been approved by Yale University Institutional
Review Boards. A written informed consent has been obtained
from each individual healthy donor, and the consent procedure
has also been approved by Yale University Institutional Boards.
Peripheral blood mononuclear cells were isolated from 5
individual healthy donors with Ficoll separation. CD4+ T cells
were enriched by negative selection (Miltenyi Biotech) and
CD4+CD25-CD45RO+CCR6+CD161+, CD4+CD25-
CD45RO+CCR6-CD161- and CD4+CD25-CD45RO-CD62L+
naı ¨ve T cells were sorted by FACS Aria (BD Bioscience). For
Th1 differentiation, naive T cells were activated with plate-
bound anti-CD3 mAb (10mg/ml) and soluble anti-CD28 mAb
(1.0 mg/ml) in serum-free media supplemented with recombi-
nant IL-12 (5 ng/ml) and anti-IL-4 (10 mg/ml) for 7 days.
Sorted CD4
+ memory T cell subsets were activated with plate-
bound anti-CD3 mAb and soluble anti-CD28 mAb, and
supplemented with IL-23 (20 ng/ml) and IL-1b (10 ng/ml) for
7 days. Intracellular staining was performed by using the
Cytofix/Cytoperm buffer set (BD Biosciences) according to the
manufacturer’s instructions. Briefly, cells were incubated for 5
hours with PMA (50 ng/ml), ionomycin (500 ng/ml) and
GolgiPlug (BD Biosciences, CA), then permeabilized with
Cytofix/Cytoperm buffer and stained with FITC-conjugated
anti-IFNc (BD Biosciences) and APC-conjugated anti-IL-17
(eBioscience, CA).
Total RNA Isolation, Microarray, Definition of Immune-
mediated Gene Loci, Enrichment and Cluster Analysis
Total RNA was isolated from naı ¨ve CD4+ T cells, Th1, Th17-
enriched and Th17-negative memory CD4+ T cells using the
RNeasy Mini Kit (Qiagen) with DNase treatment. Naı ¨ve and Th1
cells were from 4 individuals. Th17-enriched and Th17-negative
memory CD4+ T cells were from 5 individuals, and 4 of them are
the same individuals as the Naı ¨ve and Th1 group. High quality
(RIN .8.5) RNA was hybridized to the Affymetrix GeneChipR
Human Gene 1.0 ST expression arrays for gene expression
profiling. RMA normalization [37] of the intensity data was
performed using the Partek Genomics Suite. All microarray data is
MIAME compliant and the raw data has been deposited in GEO
database. The GEO accession number is GSE 32901.
Immune-mediated disease loci were defined by the inclusion as
a fine-mapping disease locus on the custom-designed Immuno-
chip. Loci were included if genome-wide significant evidence for
disease association was observed in at least one immune-
mediated disease (Crohn
1s disease, ulcerative colitis, celiac
disease, psoriasis, type 1 diabetes mellitus, rheumatoid arthritis,
multiple sclerosis, ankylosing spondylitis, systemic lupus erythe-
matosus). All European ancestry 1000 Genomes SNPs within
0.1 cM of the peak association signals were included in the fine-
mapping loci, and 1387 transcripts within the fine-mapping
boundaries were included in the enrichment analyses. For each
possible ordered pair of 2 cell types, (cell type 1, cell type 2),
where cell type belongs to the set (naive, in vitro differentiated
Th1, Th17-enriched and Th17-negative), we measure the degree
of enrichment between a set of 1387 transcripts, chosen for to
their proximity to immune-mediated disease associated loci, and
the set of up-regulated transcripts in cell type 1 relative to cell
type 2. Fisher’s exact test was used to estimate enrichment P-
values using the following steps:
(i) Calculate the P-values for upregulation of cell type 1
relative to cell type 2 for 18,524 transcripts (that are
common to both RNASeq and microarray).
(ii) From this set of 18,524 transcripts, find a subset of
transcripts, S, which are not related to autoimmune disease
loci, with the property that the median gene expression of
cell type 1 and cell type 2 for transcripts within this set, S,
equals the median gene expression within the 1387
immune mediated disease transcripts. Next merge this set
with the 1387 immune mediated disease transcripts to
create a ‘background’ set of transcripts appropriate for the
enrichment test.
(iii) Construct a 2 x 2 table of counts which assigns each of the
background transcripts to one of 4 cells depending on
whether it is among the 5% most differentially expressed
transcripts (according to P-value), and whether the
transcript is within the 1387 autoimmune transcripts or
not.
(iv) Calculate the Fisher’s exact test P-value associated with the
table constructed in (iii).
sequenced, confirming the exon contents designated. The 700 base pair transcript terminating in the intron 6 region would encode for a transcript
terminating prior to the transmembrane domain in exon 9.
doi:10.1371/journal.pone.0038510.g005
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RNA libraries were prepared according to the manufacturer’s
recommended protocol (Illumina, CA). Total RNA samples of
Naı ¨ve, in vitro differentiatedTh1, Th17-enriched and Th17-
negative CD4+ T cells from 4 individual healthy controls were
transcribed to cDNA. cDNA samples were then sheared by
nebulization (35 psi, 6 min). Duplexes were blunt ended (large
Klenow fragment, T4 polynucleotide kinase and T4 polymerase)
and a single 39adenosine moiety was added using Klenow exo
2
and dATP. Illumina adapters, containing primer sites for flow cell
surface annealing, amplification and sequencing, were ligated onto
the repaired ends of the cDNA. Gel electrophoresis was used to
select for DNA constructs 200–250 base pairs in size, which were
subsequently amplified by 18 cycles of PCR with Phusion
polymerase. These libraries were denatured with sodium hydrox-
ide and diluted to 3.5 pM in hybridization buffer for loading onto
a single lane of an Illumina GA flow cell. Cluster formation,
primer hybridization and sequencing reactions were according to
the manufacturer’s protocol. High throughput sequencing was
performed using paired end, 75 base pair reads. Two flow lanes
were used for each cDNA sample, yielding an average of 103.3
million reads per sample.
RNASeq Mapping, Estimates of Differential Expression
and Isoform Abundance
Tophat v1.3.3 [38] was used to align the RNAseq reads to the
hg19 genome. RNASeq gene expression was measured for each
gene from version 59 of the Ensembl database by Mapped
Fragments per Kilobase of Exon model per Million mapped reads
(FPKM) calculated via Cufflinks v1.2.1. The Affymetrix annota-
tion for the Human HuGene 1.0 array was downloaded and used
to annotate the microarray probes. Subsequently, microarray
intensity was calculated as the RMA-normalized log intensity for
a single chosen probe in a given gene region. Microarray intensity
and FPKM were matched on common gene name for 18,524
genes, and plotted against each other (Figure S1).
We used the program Cuffdiff to test for differential transcript
expression in each pair of cell lines. When samples were paired, it
was necessary to analyze each sample individually in Cufflinks
before combining the resulting P-values using the Fisher method to
get a single P-value for differential expression for each gene. We
made an exception to this rule for genes where the estimated log
fold changes for the 4 samples did not all have the same sign.
These genes were assigned a P-value of 1. P-values for differential
expression from the microarray data were calculated via paired t-
tests. The QQ plot (Figure 2) was created by plotting the observed
ordered negative log10 P-values for the RNASeq (or microarray)
data against the ordered negative log10 P-values that would be
expected if no genes were differentially expressed.
Quantitative Methylation Studies
Quantitative DNA methylation analysis was performed at the
Keck Core Facility at Yale University using the MassARRAY
EpiTYPER system (Sequenom, CA) according to the manufac-
turer’s instructions. Genomic DNA samples were bisulfite treated
to convert non-methylated cytosine into uracil using the EZ DNA
methylation kit (Zymo Research, CA), followed by PCR ampli-
fication using T7-promotor tagged reverse primers. After shrimp
alkaline phosphatase treatment, in vitro transcription was
performed, and the generated transcript was subjected to an
enzymatic base specific cleavage. The resulting fragments differ in
size and mass depending on the sequence changes generated
through bisulfite treatment. The fragment masses were determined
by MALDI-TOF MS and the EpiTYPER software used to
estimate percentages of methylation at CpG sites for each
analyzed fragment.
39 Rapid Amplification of cDNA Ends (39 RACE)
39 Race was performed with FirstChoice RLM-RACE Kit
(Ambio by Applied Biosystem, CA) according to manufacturer’s
protocol. 39 Race outer and inner primers were designed from
Exon 6 with Primer3 Plus, the first and nested PCR were done
using an annealing temperature of 60uC. The highly expressed
fragments after nested PCR were purified with QIAquick Gel
Extraction Kit (Qiagen, CA), and then Sanger sequenced by using
ABI 3730XL DNA Analyzer and sequence scanner v1.0 from
ABI.
Supporting Information
Figure S1 RNASeq gene expression, measure by log2
FPKM, is highly correlated with microarray gene
expression measured by log2 normalized intensity.
(Pearson correlation ranging from 0.83 to 0.85 in naı ¨ve, in vitro
differentiated Th1, Th17-negative, and Th17-enriched CD4+ T
cell subsets.
(TIFF)
Figure S2 A. Hierarchical clustering, based on normal-
ized microarray intensity, was performed for a set of
147 transcripts. The transcripts were selected to show at least
a 1.5 fold up-regulation, and a P-value for differential expression
less than 0.05 in the Th17-enriched cell subset compared to the
Th17-negative cell subset. A total of 25 transcripts, associated with
various autoimmune diseases, are designated with asterisks (*) on
the right hand side of the heatmap. B. Disease-associated
transcripts demonstrating increased expression in both Th17-
enriched and Th1 cells: IL1R2, interleukin 1 receptor 2; PFKFB3,
6-phophofructo-2-kinase/fructose-2,6-biphosphatase 3; IL18RAP,
interleukin 18 receptor accessory protein; IL18R1, interleukin 18
receptor 1; IL12RB2, interleukin 12 receptor, beta2; IL23R,
interleukin 23 receptor; ITGAX, integrin, alpha X (complement 3
receptor 4 subunit); VDR, vitamin D (1, 25-dihydroxyvitamin D3)
receptor; SMOX, spermine oxidase; ATP6V0A1, ATPase, H+
transporting, lysosomal V0 subunit. C. Disease-associated tran-
scripts demonstrating increased expression solely in Th17-
enriched cells: KLRB1, killer cell lectin-like receptor subfamily
B, member 1; IL17F, interleukin 17, F isoform; CCR6, chemokine
(C-C motif) receptor 6; CAMTA1, calmodulin binding transcrip-
tion activator 1; IL1R1, interleukin 1 receptor 1.
(TIFF)
Figure S3 A. Vista genome browser view showing
conservation scores near the IL23R promoter. In the
IL23R promoter sequences, italicized red CpGs were included in
the methylation analysis and SNPs are shown in blue. B. Fractions
of methylation at conserved CpG promoter sites estimated by mass
spectrometry (N=5) for IL22, RORC, IL7R, IL18RAP and IL17F
promoters. A paired t-test were used to test for differential
methylation for the comparisons: naı ¨ve vs. Th1 and Th17-negative
vs. Th17-enriched; *P,0.05, **P,0.01, ***P,0.001.
(TIFF)
Figure S4 Confirmation of sequence contiguity for
IL23R isoforms terminating in the extended exon 6
region. The reverse primer (59 GGGTTGAAAAGCAAAT-
TATTGGTAACTA - 39) was designed from the extended exon 6
region, with forward primers designed from exons 1 through 6.
The forward primers were: Exon 1, 59 - GGTCAAGCGAT-
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TACTCTTCAGCTGGTGTC -39; Exon 3, 59 - TATTGC-
CAAGCAGCAATTAAGAAC -39; Exon 4, 59 - AGAAGAG-
CAACATGATCTCACCTCAA -39; Exon 5, 59 -
CAAGGCTACAACAAACCAAACTT -39; Exon 6, 59 -
CAAGGCTACAACAAACCAAACTT - 30.
(TIFF)
Table S1 Known GWAS disease associations within upregu-
lated transcripts in Th17-enriched cells compared to Th17-
negative CD4+ T cells according to RNASeq.
(XLS)
Table S2 Known GWAS disease associations within upregu-
lated transcripts in Th17-enriched cells compared to Th17-
negative CD4+ T cells according to Microarray.
(XLS)
Author Contributions
Conceived and designed the experiments: WZ JF EE RAF CA HZ JHC.
Performed the experiments: WZ SN. Analyzed the data: WZ JF AL KH
GG JHC. Wrote the paper: WZ JF JHC.
References
1. Zenewicz LA, Abraham C, Flavell RA, Cho JH. (2010) Unraveling the genetics
of autoimmunity. Cell 140: 791–797.
2. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, et al. (2006) A
genome-wide association study identifies IL23R as an inflammatory bowel
disease gene. Science 314: 1461–1463.
3. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, et al. (2007) A large-
scale genetic association study confirms IL12B and leads to the identification of
IL23R as psoriasis-risk genes. Am J Hum Genet 80: 273–290.
4. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, et al. (2007)
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies
autoimmunity variants. Nat Genet 39: 1329–1337.
5. Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, et al. (2010)
Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling.
Nature 467: 967–971.
6. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, et al. (2002) A receptor
for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel
cytokine receptor subunit, IL-23R. J Immunol 168: 5699–5708.
7. Anderson CA, Boucher G, Lees CW, Franke A, D’Amato M, et al. (2011) Meta-
analysis identifies 29 additional ulcerative colitis risk loci, increasing the number
of confirmed associations to 47. Nat Genet 43: 246–252.
8. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, et al. (2010)
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s
disease susceptibility loci. Nat Genet 42: 1118–1125.
9. Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, et al. (2006) The
orphan nuclear receptor RORgammat directs the differentiation program of
proinflammatory IL-17+ T helper cells. Cell 126: 1121–1133.
10. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, et al. (2008) Human
interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor.
J Exp Med 205: 1903–1916.
11. Kleinschek MA, Boniface K, Sadekova S, Grein J, Murphy EE, et al. (2009)
Circulating and gut-resident human Th17 cells express CD161 and promote
intestinal inflammation. J Exp Med 206: 525–534.
12. Maggi L, Santarlasci V, Capone M, Peired A, Frosali F, et al. (2010) CD161 is
a marker of all human IL-17-producing T-cell subsets and is induced by RORC.
Eur J Immunol 40: 2174–2181.
13. Izadpanah A, Dwinell MB, Eckmann L, Varki NM, Kagnoff MF. (2001)
Regulated MIP-3alpha/CCL20 production by human intestinal epithelium:
mechanism for modulating mucosal immunity. Am J Physiol Gastrointest Liver
Physiol 280: G710–719.
14. Varona R, Villares R, Carramolino L, Goya I, Zaballos A, et al. (2001) CCR6-
deficient mice have impaired leukocyte homeostasis and altered contact
hypersensitivity and delayed-type hypersensitivity responses. J Clin Invest 107:
R37–45.
15. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, et al. (2007)
Phenotypic and functional features of human Th17 cells. J Exp Med 204: 1849–
1861.
16. Izcue A, Hue S, Buonocore S, Arancibia-Carcamo CV, Ahern PP, et al. (2008)
Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent
colitis. Immunity 28: 559–570.
17. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, et al. (2003) Interleukin-23
rather than interleukin-12 is the critical cytokine for autoimmune inflammation
of the brain. Nature 421: 744–748.
18. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, et al. (2006) IL-
23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent
mechanisms with implications for psoriasis pathogenesis. J Exp Med 203:
2577–2587.
19. Ahern PP, Schiering C, Buonocore S, McGeachy MJ, Cua DJ, et al. (2010)
Interleukin-23 drives intestinal inflammation through direct activity on T cells.
Immunity 33: 279–288.
20. Wang Z, Gerstein M, Snyder M. (2009) RNA-Seq: a revolutionary tool for
transcriptomics. Nat Rev Genet 10: 57–63.
21. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, et al. (2011) Dense
genotyping identifies and localizes multiple common and rare variant association
signals in celiac disease. Nat Genet 43: 1193–1201.
22. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. (2009)
Potential etiologic and functional implications of genome-wide association loci
for human diseases and traits. Proc Natl Acad Sci U S A 106: 9362–9367.
23. Bird A. (2002) DNA methylation patterns and epigenetic memory. Genes Dev
16: 6–21.
24. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, et al. (2008) Genome-
scale DNA methylation maps of pluripotent and differentiated cells. Nature 454:
766–770.
25. Sarin R, Wu X, Abraham C. (2011) Inflammatory disease protective R381Q
IL23 receptor polymorphism results in decreased primary CD4+ and CD8+
human T-cell functional responses. Proc Natl Acad Sci U S A 108: 9560–9565.
26. Di Meglio P, Di Cesare A, Laggner U, Chu CC, Napolitano L, et al. (2011) The
IL23R R381Q gene variant protects against immune-mediated diseases by
impairing IL-23-induced Th17 effector response in humans. PLoS One 6:
e17160.
27. Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, et al. (2007) A genome-wide
association study of global gene expression. Nat Genet 39: 1202–1207.
28. Kang J, Cho J, Zhao H. (2010) Practical issues in building risk-predicting models
for complex diseases. J Biopharm Stat 20: 415–440.
29. Yu RY, Gallagher G. (2010) A naturally occurring, soluble antagonist of human
IL-23 inhibits the development and in vitro function of human Th17 cells.
J Immunol 185: 7302–7308.
30. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, et al. (2009) Late
developmental plasticity in the T helper 17 lineage. Immunity 30: 92–107.
31. Bending D, De la Pena H, Veldhoen M, Phillips JM, Uyttenhove C, et al. (2009)
Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells
in NOD/SCID recipient mice. J Clin Invest 119: 565–572.
32. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, et al. (2011) Fate mapping
of IL-17-producing T cells in inflammatory responses. Nat Immunol 12: 255–
263.
33. Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, et al. (2006)
Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune
pathology. Immunity 25: 309–318.
34. Hedrick MN, Lonsdorf AS, Shirakawa AK, Richard Lee CC, Liao F, et al.
(2009) CCR6 is required for IL-23-induced psoriasis-like inflammation in mice.
J Clin Invest 119: 2317–2329.
35. Wei G, Wei L, Zhu J, Zang C, Hu-Li J, et al. (2009) Global mapping of
H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate
determination of differentiating CD4+ T cells. Immunity 30: 155–167.
36. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, et al. (2005)
Mapping determinants of human gene expression by regional and genome-wide
association. Nature 437: 1365–1369.
37. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003)
Exploration, normalization, and summaries of high density oligonucleotide array
probe level data. Biostatistics 4: 249–264.
38. Trapnell C, Pachter L, Salzberg SL. (2009) TopHat: discovering splice junctions
with RNA-Seq. Bioinformatics 25: 1105–1111.
Effector CD4+ T Cell Expression Signatures
PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e38510